Machine learning provides a broad framework for addressing high-dimensional prediction problems in classification and regression. While machine learning is often applied for imaging problems in medical physics, there are many efforts to apply these principles to biological data towards questions of radiation biology. Here, we provide a review of radiogenomics modeling frameworks and efforts towards genomically-guided radiotherapy. We first discuss medical oncology efforts to develop precision biomarkers. We next discuss similar efforts to create clinical assays for normal tissue or tumor radiosensitivity. We then discuss modeling frameworks for radiosensitivity and the evolution of machine learning to create predictive models for radiogenomics.
5.3.4
Challenges of modeling therapeutic ratio. 
Introduction
In radiotherapy, radiogenomics is the study of the totality of genomic variation that affect the response of normal and tumor tissue to radiation. [1] [2] [3] There is significant interest in incorporating radiogenomics to guide personalize radiotherapy treatments. 4, 5 Machine learning (ML) rose as a merger of computer science and statistics that provides a computationally-scalable framework for addressing highdimensional classification and regression for prediction problems. ML is widely used in genomics for various tasks [6] [7] [8] and there are similar efforts to apply ML to high-dimensional radiogenomics datasets to create predictive models. 9 Like many fields in medicine, radiation oncology has taken significant interest in applying ML for several aspects of its practice. [10] [11] [12] [13] [14] Notable cooperative efforts in the United States include the American Association of Physicists in Medicine (AAPM) Practical Big Data Workshop (annually since 2017) 15 and a recently concluded National Cancer Institute (NCI) workshop on Artificial Intelligence in Radiation Oncology in April 2019.
In this review article, we begin with a background of genomically-guided therapies in medical oncology. We then contrast this with radiogenomics, beginning with efforts to predict normal tissue radiosensitivity before moving to the prediction of tumor radiosensitivity. Next, we discuss various frameworks for modeling radiosensitivity and how radiogenomics can augment these models. We then discuss the role and application of ML methods for specific radiogenomics applications to predict normal tissue and/or tumor radiosensitivity.
Precision oncology
While its precise definition is evolving, "precision oncology" generally is described as using genetic information to find targets for systemic agents. 16 Early examples of precision oncology focused on single mutations, such as imatinib to target BCR-ABL translocation in chronic myelogenous leukemia or trastuzumab to target HER2-neu oncogene amplification in breast cancer. In the last half decade, targeted therapies for specific tyrosine kinase mutations in lung cancer and melanoma have become standard of care.
NCI precision medicine trials
In March 2017, the US Food and Drug Administration (FDA) granted a tissue-agnostic "blanket approval" to the PD-1 inhibitor pembrolizumab for any metastatic or unresectable solid tumor with high microsatellite instability or deficiency in mismatch repair. 17 The rationale was the improved response rate and progression-free survival seen in colorectal tumors with genomic instability due to higher number of tumor neoantigens and lymphocytic infiltrates. 18 This approval marked the first time the FDA approved a drug for specific mutations independent of tissue type.
We can expect this pattern will only increase as the NCI is funding several "precision medicine" trials that are weighing mutational burden to guide therapy over the traditional method of being tissue-specific. 19 NCI-MATCH (for specific gene mutations) and NCI-MPACT (for mutations in specific pathways) are taking this tissue-agnostic, mutation-specific approach to targeted therapy. 20 The NCI-COG Pediatric MATCH is a similar to NCI-MATCH except patients will also have germline sequencing to determine whether the tumor genetic variants were inherited or not.
Biomarkers for decision making
In oncology, prognostic biomarkers provide treatment-agnostic information about a patient's outcome whereas predictive biomarkers provide information about whether a patient will benefit from a specific treatment. 21 The key point in the NCI-funded precision oncology trials is that regardless whether a biomarker is prognostic or predictive, 22 the result should alter the management of a patient. Even though prognostic biomarkers do not predict for benefit from a specific therapy, they can still change management in the right clinical context. In prostate cancer, serum prostate specific antigen (PSA) and pathologic Gleason grade are well-established prognostic biomarkers. 23 However, given that favorable PSA and Gleason grade are associated with a 99.9% 15-year survival from prostate cancer without upfront treatment, 24 the standard of care is to recommend against upfront radical treatment in patients in this very low risk category to avoid the toxicity of local treatment. 25 Similarly in gene panels, breast cancer patients who met criteria for adjuvant chemotherapy but had a low Oncotype DX 26 Recurrence Score ® ≤11 were prospectively given hormone therapy alone and observed to have 5-year recurrence rate of only 1-2%. 27 Even in the absence of randomized evidence for this low risk category, the standard of care is to avoid the toxicity of chemotherapy in this low risk group.
In general, prognostic models that were not trained on an untreated cohort have limited ability to alter management as it can be difficult to distinguish causal effect of treatment vs. favorable biology of a treated cohort. For example, Speers et al. created a radiosensitivity signature for breast cancer local recurrence by training and validating on two cohorts treated with adjuvant radiation. 28 The authors note, however, that their signature is unable to differentiate between a cancer refractory (or sensitive) to radiation vs. a cancer with aggressive (or indolent) biology.
Further confusion occurs when a biomarker appears to have both prognostic and predictive value. While temozolomide chemotherapy has shown to significantly increase overall survival in O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter-methylated glioblastoma, this benefit is significantly attenuated (if it exists at all) in non-MGMT promoter-methylated glioblastoma. 29, 30 However, the mutation itself seemed to have prognostic significance independent of temozolomide, with the recent NOA-09 trial of only MGMT promoter-methylated patients showing unprecedented survival of 31 months in the standard arm. 31, 32 While there can be vigorous debate about whether a biomarker is predictive or prognostic, [33] [34] [35] [36] the focus should remain on the potential for a biomarker to alter clinical management.
Normal tissue radiosensitivity
Radiation oncology generally aims for 5-10% clinically-significant toxicity to organs at risk in clinical trials. As a result, the patients with the most radiosensitive normal tissue ultimately determine the limit for the maximum dosage for all patients. 4 It is no coincidence that the adjacent organ-at-risk dose tolerance and the recommended prescription dose mirror each other for most solid tumors. In contrast, medical oncology trialists will often accept in excess of 60% grade 3+ toxicities for advanced or metastatic disease. [37] [38] [39] These studies suggest that patients with more advanced disease are more willing to accept higher toxicity for an improved probability of survival, which is in agreement with a focus on better prediction of individualized toxicity.
Improving treatment planning
Normal tissue radiotherapy response depends on several factors. Ever since the early days of isoeffect curves, we have known that different tissue types have different radiosensitivities. To address this, organspecific guidelines were published in the QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) special edition of the Red Journal in 2010. 40 However, much progress has been made in the 9 intervening years. QUANTEC was published during a transition period from 3D conformal radiation to intensity-modulated radiation therapy (IMRT), yet QUANTEC dose tolerances have commonly carried over for IMRT planning. Given the improved conformality of moderate-high dose region in IMRT, these constraints likely represent overly conservative measures for most organ sites. Hypofractionation-both moderate and stereotactic-level-was also not addressed but has since become standard of care for several of the most commonly treated organ sites. ASTRO guidelines for hypofractionated or stereotactic treatment have published within past 2 years for lung, 41 prostate, 42 and breast cancer. 43 Since QUANTEC, there have been similar efforts by PENTEC 44 (Pediatric Normal Tissue Effects in the Clinic) and the AAPM working group HyTEC 45 (Hypofractionation Treatment Effects in the Clinic) to determine normal tissue effects for pediatric patients and hypofractionated regimens, respectively.
Genomic basis for radiosensitivity
While these advances by QUANTEC, PENTEC and HyTEC hold significant promise, they focus primarily on dose constraints and largely omit non-dosimetric clinical factors which can affect organ function following radiotherapy, such as diabetes, vasculopathy, hypertension or smoking. 46 Efforts from the 1980-1990s studying skin toxicity in breast cancer suggested a patient's toxicity could be tissue-specific, 47 temporallyspecific 48 (i.e., acute did not necessarily predict for late toxicity) and dominated by a genetic as opposed to a dosimetric component. 49 These works provided early evidence of genetic predisposition to radiosensitivity and suggested that there were not only rare-yet-highly-penetrant radiosensitivity genes (i.e. ATM), but also more subtle genetic biomarkers that do not manifest until directly insulted with radiotherapy.
SNP analysis: candidate gene
With the advent of genome-wide genotyping and next-generation sequencing in the 2000s, cost-effective and high-throughput efforts to investigate the genetic component of radiotherapy toxicity became possible. Analysis with single nucleotide polymorphisms (SNPs), which are single nucleotide variations between individuals, was-and still is-a popular method due to its low cost and ability to capture the majority of common (allele frequency ≥ 5%) SNPs across the genome. Most of the early radiogenomics studies used a candidate gene approach where SNPs were pre-selected for their proximity to genes known to be involved in cellular radiosensitivity. Early candidate gene studies were often small, underpowered, and performed with a poor understanding of important statistical issues, namely, false discovery due to uncorrected multiple hypothesis testing. 50 Unsurprisingly, subsequent validation studies with independent cohorts would fail to replicate these association and also suggest publication bias. 51, 52 In response, the international Radiogenomics Consortium (RgC) was formed in 2009 to pool individual cohorts and facilitate cooperative research efforts. 53, 54 Newer candidate gene analyses have generally validated findings on independent cohorts. RgC members have found and validated SNPs associated with late skin, fibrotic, and overall toxicity after breast cancer radiotherapy upstream to inflammatory cytokine TNFA 55 (rs1800629, rs2857595) and within base-excision repair gene XRCC1 (rs2682585). 56 A large metaanalysis validated the association of rs1801516 in DNA double-strand break (DSB) repair gene ATM with several acute and late toxicities in breast and prostate cancer, thus mimicking a milder phenotype of ataxia-telangiectasia syndrome. 57 The Liao group has identified and validated SNPs to predict for Grade ≥3 toxicity after lung cancer radiotherapy. These include SNPs in heat shock protein HSPB1 associated with pneumonitis 58 and esophagitis, 59 and rs1800469 in profibrotic cytokine TGFB1 associated with esophagitis. 60 The role of the rs1800469 SNP remains unclear, and may be tissue-specific. RgC members performed an individual-patient meta-analysis of 2782 patients from 11 cohorts to assess for association of rs1800469 with late fibrosis or late overall toxicity (using a harmonized average score) in breast radiotherapy and found no association with multivariable odds ratio 0.98 (95% confidence interval 0.85-1.11). 61 
SNP analysis: genome wide association studies
An alternative to candidate gene studies is genome-wide association analysis (GWAS). Contrary to the targeted candidate gene approach, GWAS casts a wide net to sieve out moderate levels of signal in noisy genomic data. 52 The threshold for statistical significance is more stringent to account for the increased number of independent hypotheses performed in GWAS (one per SNP) and thus larger sample sizes are typically required to find statistically-informative associations. Recent GWAS , including meta-analysis, by RgC members have identified several novel SNPs associated with genes which were not previously linked to radiotherapy toxicity. 63 These genes include TANC1, which encodes a repair protein for muscle damage, 64 and KDM3B and DNAH5, which encode proteins expressed in urinary tract and were associated with increased urinary frequency and decreased urinary stream, respectively. 65 
Beyond SNPs
Copy number variation (CNV) or gene dosage is another genetic alteration that is estimated to account for 4.8-9.5% of the genome. 66 A CNV exists when a DNA segment 1 kb to several Mb in length is either deleted or duplicated compared to a reference genome. 67 The objective of CNV analysis is to determine how many copies of a gene regions deviates from two, representing a reference gene with one copy from each homologous chromosome. CNVs have been implicated in several diseases, but their role in radiotherapy toxicity is nascent. In a proof-of-concept study, Coates et al. incorporated XRCC1 SNP and CNV features into classic models to improve performance. 68 In a very large pre-clinical study, Yard et al. illustrated the rich space of CNVs, gene mutations, and gene/gene set expressions by exposing over 500 cell lines to radiation. 69 Radiosensitivity was enriched in gene sets associated with DNA damage response, cell cycle, chromatin organization, and RNA metabolism.
In contrast, radioresistance was associated with cellular signaling, lipid metabolism and transport, stemcell fate, cellular stress, and inflammation.
Tumor radiosensitivity
Tumor radiogenomics has focused on finding transcriptomic assays to determine radiosensitivity. 3, 70 The general goal of these assays or models is to predict whether an individual benefit would be more served by radiotherapy compared to an alternative treatment.
Tumor genomics should be distinguished from germline genomics as the former is usually using genetic information from tumor tissue whereas the latter is using DNA taken from normal tissues, typically blood or saliva ( Table 1 ). There are exceptions as described below with MRE11A and later with multi-omics models by the El Naqa group. 71 Table 1 : Examples of tumor genomics assays/models and consortia for germline genomics
Gene expression to predict radiotherapy benefit
Pre-treatment bladder cancer expression of DSB repair gene MRE11 was found to be predictive of survival following radical radiotherapy but not cystectomy by the Kiltie group, 72 a result that was independently verified by Laurberg et al. 73 Interestingly, the SNP rs1805363 in MRE11A was also found predictive of survival in a gene-dosage effect in patients with bladder cancer treated by radical radiotherapy but not by cystectomy. 74 New work by the Kiltie group aimed to standardize and develop a clinical assay for MRE11 immunohistochemistry assay across several centers in the United Kingdom using transurethral resection of bladder (TURBT) samples from prior bladder-preservation trials. 75 However, they were unable to replicate prior results, which was attributed to problems in automatic staining and poor scoring reproducibility among histopathologists.
The Post-Operative Radiation Therapy Outcomes Score (PORTOS) is a 24-gene predictive assay that was retrospectively trained on post-prostatectomy prostate cancer samples from patients, some of who received postoperative radiotherapy. 76 The authors used gene ontology to find gene sets enriched for DNA damage and radiation response. Using a final pool of 1800 genes, a univariable screen was used for ranking, followed by ridge regression-penalized Cox modeling of distant metastasis free survival to determine which patients would benefit from post-operative radiation therapy. The radiosensitivity index (RSI) was developed at Moffitt Cancer Center to predict radiosensitivity in several tumor cell lines. 77 The RSI signature is a linear regression of the expression of 10 genes (AR, cJun, STAT1, PKC, RelA, cABL, SUOMO1, CDK1, HDAC1, IRF1) with the outcome variable being survival fraction at 2 Gy (SF2). The selected genes are implicated in pathways involved in DNA damage response, histone deacetylation, cell cycle, apoptosis and proliferation. In patients, RSI predicted for improved progression free survival in cohorts treated with adjuvant radiation but not in unirradiated controls in several tissue types, including breast cancer, 78 lung cancer, 79 and prostate cancer. 80 More recently, Scott et al. combined RSI with the linear quadratic model to create the Genome Adjusted Radiation Dose (GARD). 81 The goal of GARD is to unify a model of both radiobiologic and genomic variables to predict for radiation response, and provide a quantitative link from genomics to clinical dosing. There is discussion regarding whether GARD is truly prognostic or predictive as the radiation dosage component is a modifiable input. 33, 34 Another class of molecules that has gained interest are micro RNAs (miRNA) which are short, stable sequences of RNA which act to inhibit expression of messenger RNA (mRNA). 82 Pretreatment serum levels have been found to correlate with radiotherapy response cancers of the lung 83 and head and neck. 84, 85 miRNA upregulation can occur just hours after ionizing radiation. 86 
Prognostic or predictive radiation signatures
As there was no alternative treatment that patients could have received instead of radiation in the populations used to train RSI/GARD or PORTOS, it remains unclear whether these tests are acting as specific biomarkers of radiotherapy benefit or whether they serve as general markers for treatment sensitivity. In other words, perhaps a similar benefit or even increased benefit would be seen with systemic therapy or other therapy. Without comparison to alternative therapies, there will remain a question of whether radiation is the correct choice in a space increasingly crowded with targeted therapies, immunotherapy, and salvage surgery. As the MRE11 studies did train models on patients that received either radical radiotherapy or cystectomy, it would be correct to say that MRE11 expression does predict for radiotherapy benefit vs. surgery. While these tumor radiosensitivity assays remain to be prospectively or randomly validated, MRE11, PORTOS, and RSI/GARD are a promising harbinger of future radiogenomics assays to determine benefit from radiation.
Tumor sensitivity assays remain of active interest. In the newly published Children's Oncology Group ACNS 0121 phase 2 trial, improved event free survival (EFS) was seen in pediatric infratentorial ependymomas receiving chemoradiation who had focal copy number gain on chromosome 1q compared to those without 1q gain (83% vs. 47%, p=.0013). 87 As there was no cohort with focal 1q copy number gain that did not receive chemoradiation therapy, we do not know whether this mutation is predictive of chemoradiation response or general prognostic indicator.
Radiogenomic modeling: mechanistic, data-driven and machine learning methods
The following section highlights methods and examples of different frameworks for radiogenomics modeling. We first discuss augmentation strategies for "classical" (dose-& volume-based) outcomes models to allow the integration clinical and biological data ("augmentation"). We then discuss data-driven modification of these models as well as data-driven models that use machine learning.
Classical mechanistic models
Normal tissue complication probability (NTCP) models attempt to predict the risk of specific normal tissue side effects induced by radiotherapy. Examples include radiation fibrosis in the lungs or erectile dysfunction after prostate radiotherapy. Until recently, such predictive models have relied almost exclusively on mechanistic interpretations of dose and volume data to understand the effects of ionizing radiation. 88, 89 It is now apparent that genetic and biological factors can play a significant role in determining and modulating tissue radiosensitivity, often in non-linear ways. 90 Pragmatically, NTCP models based on dosimetry-alone risk lacking robustness across cohorts potentially limiting their usefulness clinically.
Biological risk factors integrated into classical outcome models generate 'augmented' (or 'mixed') models. This approach can also be extended to clinical risk factors as well. The impact of integrating a validated biological risk factor is visualized in Figure 1a in the change of NTCP curve slope and absolute value according to different generalized equivalent uniform doses (gEUDs). A corresponding shift is showcased in Figure 1b for the same theoretical, dichotomous biological risk factor (present or absent) but is plotted with separate dose and volume components in three-dimensional space. These figures use mock input data but show changes similar in magnitude to those in literature. [90] [91] [92] Figure 1: Theoretical impact of integrating validated biological risk factors on predicted NTCP curves (a) and surfaces (b). In (a), NTCP values were generated using the modified mechanistic Lyman-Kutcher-Burman LKB and mock generalized equivalent uniform dose (gEUD) values were input to yield NTCP values with or without a risk factor (as indicated). Surfaces were similarly generated with mock values for dose and volume parameters making separate gEUD-based planes.
In order to generate NTCP curves, there exists two overarching modeling approaches: data-driven and mechanistic. Data-driven approaches use statistical techniques to identify trends and correlations in data while mechanistic approaches (also known as analytical techniques) rely on certain simplifying assumptions to reflect experimental observations. The methodology for augmenting a model can vary widely depending on the chosen strategy and is therefore equally important to consider. In the below sections, we discuss types of biological factors used in augmenting models and associated strategies with relevant examples.
A B
Integration of biological variables
SNPs reflect single changes in nucleotide sequences and their incorporation into NTCP models has become more common recently although most findings remain to be validated on large cohorts. If found in coding regions, SNPs may induce conformation or enzymatic changes to transcripts or proteins. For NTCP modeling, these changes could affect DNA repair capabilities, signal transduction, or other elements of the DNA damage response (DDR) cascade. 93 In the case of SNPs that do not reside in protein coding regions, mechanistic influence on outcomes is less clear but could theoretically relate to transcript splicing, binding, or degradation. 94 As discussed above, SNPs of interest were historically sought using candidate gene approaches and most reports related to DDR pathways. 2, 95 Previously, our group demonstrated that more substantial changes to the genome could be useful for outcome modelling in addition to SNPs for predicting late effects in prostate cancer radiotherapy. 68 Resulting radiogenomic models incorporating SNPs, CNVs, and dosimetry led to increased cross-validated predictive power when compared to dosimetric-or genetic-only models. The CNV of DNA repair gene XRCC1 was found to be particularly useful for predicting severe RB (Grade ≥3) or ED (Grade ≥1) when combined with dosimetry. Though improvement in cross-validated prediction performance was found for both data-driven and mechanistic modeling strategies, performance was higher in the case of data-driven models compared to mechanistic ones. Given the limited sample size (n=54), the worse performance of the mechanistic model may reflect incorrect assumptions introducing a bias, which can be compensated for in the data-driven model. Thus, the relative difference in performance observed in the study may be dependent on the modeling frameworks employed.
In the case of augmenting existing mechanistic models, it is important to consider how variables such as the binary presence of genetic variants are incorporated mathematically to avoid nullifying model output in the absence of the risk factor; this principle applies similarly to clinical risk factors. The use of dosemodifying factors (DMFs) maps existing parameters into an exponential function to avoid misbehaved outputs (e.g., when it goes to zero or ∞). 68, 91, 96 In contrast, data-driven approaches are readily able to integrate dichotomous and continuous data.
Modulating dose in mechanistic models
The most frequently employed mechanistic NTCP in use is the Lyman-Kutcher-Burman (LKB) model (Eq. 1a-c):
where Φ( ) is the normal cumulative distribution function:
consisting of:
where TD 50 (1) is the dose at which NTCP is 50% for an endpoint, m the slope, and TD 50 (V) is the partial volume tolerance dose, and n is the tissue-specific volume exponent.
The LKB model stratifies patient risk according to how much larger or smaller their gEUD is relative to the TD 50 . Note that the gEUD is a three-dimensional DVH reduction technique and so spatial information on dose distribution is not fully retained. The modified LKB model 98 (Eq. 2a-b) allows for the inclusion of biological risk factors whether they are dichotomous or not:
where each DMF is defined by:
wherein δk is the risk-factor weight for risk-factor k, and R k indicates the presence (R k =1) or absence (R k =0) of the risk-factor for a given patient.
The GARD/RSI model discussed above is a practical example of augmenting the linear-quadratic model of cell kill by adding gene-expression derived parameters to create a patient-specific radiosensitivity assay. 81 
Data-driven methods: statistical models
Data-driven models (also known as phenomenological models) are built on statistical techniques that are empirical and frequentist. 11 The robustness of data-driven models relates to how often observations (data or variables) can be related to an outcome according to certain relationships (equations). As such, datadriven NTCP models may be able to identify models that perform better than mechanistic counterparts, given sufficient data, or that depart significantly from standard therapeutic strategies, such as charged particle therapy. 99 The most common type of data-driven NTCP model is regression-based and sigmoidal. This is due the speed of regression and the experimentally observed sigmoidal relationship seen with ionizing radiation and cell death. Data-driven modeling frameworks using sigmoidal link functions can fit tumor control probability (TCP) data but are more often employed in NTCP modelling given the success and adoption of the linear-quadratic formulation in estimating cell-kill experimentally. The most commonly used link functions are the inverse of the normal cumulative distribution function, or probit (Eq. 3), and inverselogit (Eq. 4):
where ( ) is the generalized linear formulation of the input variable(s), x i : (5) having β as coefficients that are identified via optimization, e.g. maximum likelihood estimation.
Increased generalizability for data-driven models may also originate from frameworks having to first choose whether to include a variable or not (model order estimation) prior to fitting coefficients. 100 In contrast, mechanistic modelling approaches require that some or all parameters be included and therefore only be modulated, which may limit generalizability due to forcing features into the model.
The PORTOS assay discussed above is a practical example of augmenting Cox regression survival analysis with gene-expression derived tumor radiosensitivity. 76 
Data-driven methods: interpretable machine learning
Machine learning (ML) evolved from a recent cross-pollination between computer science and statistics. As owed to their computer science origin, most ML models are "data-driven" techniques as they do not attempt to model simplified mechanisms 101 (as is done in the mechanistic/analytical approach) and instead statistically translate inputs into probabilities that appear sigmoidal, though the specific link function is a user-set hyperparameter. Due to the focus on using data to make predictions but not in inferring the processes behind data generation, many ML methods are rightly described as having poor interpretability. Improving interpretability is of particular value in clinical decision support models [102] [103] [104] and is a high priority research area in ML, being the subject of a Neural Information Processing Systems symposium in 2017. 105 Some data-driven models in ML attempt to provide a more interpretable context. The progression of Bayesian network approaches by the El Naqa group provides a case study of more interpretable, multiobjective modeling in radiogenomics, as described below.
Bayesian networks
Bayesian networks (BN) are directed graphical models with probability distributions. 106 The graph is represented by nodes (vertices) connected by links (edges) that represent probabilistic relationships between the variables. The graph then captures joint distributions between subsets of the variables. In fact, relationship between nodes in a BN can be deconstructed into a series of joint probabilities. BNs are subject to an important restriction there must not be a closed path from a node to another node along links following the direction of the arrows. Despite their name, they can be used for either frequentist or Bayesian inference. 107 Like decision trees, BNs are graph-based methods that are reasonably interpretable and can incorporate variables from different domains without extensive pre-processing. A disadvantage is that continuous
..,n, j = 1,...,s j=1 s å variables are typically discretized as many BN learning algorithms cannot efficiently handle continuous variables and common software packages do not support continuous variables. 108 In radiogenomics, BN nodes represent genes or proteins while the links between them represent probabilistic similarities or interactions. 70 Due to these advantages, BNs have been used to incorporate both clinical and genomic variables to predict local control and/or toxicity.
Single objective prediction: local control or toxicity
Oh et al. used BN on two separate patient cohorts of locally-advanced non-small cell lung cancer (NSCLC) to predict local control (LC). 71 The first cohort of 56 patients included clinical and dosimetric data. The second cohort of 18 patients also had serum markers drawn pre-and during-treatment: transforming growth factor β, interleukin 6, angiotensin converting enzyme, and osteopontin. Despite the small numbers, better performance was noted when clinical, dosimetric, and molecular data were all used.
This BN framework was also applied to 54 locally-advanced NSCLC patients to predict Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade 2+ radiation pneumonitis (RP2). Initially, a limited set of pre-and during-treatment molecular biomarkers was used along with clinical/dosimetric features (i.e., lung V20) 109 but this was subsequently expanded to a heterogeneous set of 200 features, which included SNPs, cytokines and micro RNA (miRNA) biomarkers. 110 Predictive performance for these studies reached area under the receiver operating curve (AUROC) >0.80.
Multi-objective prediction: local control and toxicity
Prior radiogenomics studies have generally focused separately on either tumor control or toxicity. More recently, Luo et al. demonstrated a multi-objective approach using BN to simultaneously model LC and RP2 in a cohort of 118 NSCLC patients treated with radiotherapy. 111 A total of 297 clinical, dosimetric, radiomic, and genomic features were initially considered. The genomic features were pre-selected from literature review and included micro RNA (miRNA), SNPs, and cytokine levels in serum. The cytokine and the metabolic radiomic features had values both pre-and during-treatment. By first training individual BNs for LC and RP2, the authors were able consider a smaller feature set of about 50 (i.e., only features important for either LC or RP2) to optimize a unified multi-objective BN that simultaneously modeled LC and RP2. This process was repeated using pre-treatment or during-treatment variables. While the validation set was heavily skewed with only 3/50 patients having RP2, this work does provide a conceptual framework that accounts for both LC and toxicity.
Challenges of modeling therapeutic ratio
The therapeutic ratio (therapeutic index) refers to the ratio of tumor response for a fixed level of normal tissue damage. 112 Like many tradeoffs in statistics and ML-bias/variance, sensitivity/specificity-the multi-objective tradeoff between tumor control and toxicity in modern treatment planning follows 5 the principles of Pareto optimality or efficiency where one outcome cannot be improved without worsening another. 113 While the work by Luo et al. demonstrates the feasibility of a multi-objective ML model that optimizes a joint AUROC, it does not allow one to give relative weight to LC vs. toxicity. There are several complicated issues to consider. First, LC and toxicity are not independent events as local recurrence in lung cancer after first-line therapy generally leads to additional salvage treatments, which could include additional radiation, surgery and/or systemic therapy. The toxicity profile is now magnified with no guarantee of a linear increase in toxicity. Secondly, RP2 may be an overly conservative endpoint as CTCAE v3.0 Grade 2 pneumonitis is defined as "symptomatic, not interfering with ADL." This issue relates to the differing weights that patients and physicians place on LC and toxicity. Patients may value LC more than toxicity due to fear of recurrence 114, 115 whereas physicians may weigh toxicity more than LC. 116 Whereas a tumor recurrence may be attributed to aggressive biology, physicians can be more certain of therapy-induced toxicity, which can induce recall bias of patients who had bad toxicity. Lastly, it can be very difficult to assess adverse events. Clinicians tend to underreport subjective treatment toxicities compared to patients, which is the impetus behind patient-reported outcomes. 117, 118 In the setting of a multi-objective model, being able to precisely define toxicity becomes of upmost importance due to the direct relationship with tumor control. Wider adoption of patient-reported outcomes could partially alleviate this issue. The addition of transcriptomic or proteomic information from the tumor tissue itself (instead of circulating cytokines) would also likely improve the assay.
In the future, we will likely see tumor expression panels such as PORTOS and GARD/RSI combined with germline toxicity panels to determine multi-objective optimization for therapy aggressiveness. Such radiogenomic approaches that can increase the therapeutic ratio are sorely needed.
Data-driven methods: high dimensionality machine learning
While many of the classic ideas and methods in machine learning (ML) were developed several decades ago, the exponential increase in computing power 119 has recently allowed high-dimensional ML models to be trained in a reasonable timeframe. However, there is often interest in only using certain features of the dataset. Libbrecht and Noble describe three reasons for feature selection in machine learning for genomics: (1) identify a subset of features that retains good predictive performance, (2) understand biology through the principle of parsimony, and (3) improve performance by removing variables that are contributing noise. 7 The authors note that it is usually very difficult to perform all three simultaneously. Feature selection in genomics is difficult not only due to the large number of features (i.e. SNPs, CNVs, etc) involved, but also due to the complex biology represented. This complexity can result in low "signal to noise" that can make predictive models difficult to train.
High-dimensional feature selection is an active area of research in genomics. 120 More generally, it has long been an active area of research among statisticians, particularly so for regression problems. Arguably, these efforts began with the introduction of forward variable selection, 121 where it has since been established that forward and related methods of stepwise regression are fraught with numerous inferential challenges. 122 Modern approaches to variable (i.e., feature) selection in regression and classification vary in scope and complexity, including approaches that utilize univariate screening (or filtering) procedures, 123, 124 penalized regression or classification methods (e.g., lasso, 125 elastic net 126 ), and combinations thereof. 127 The statistical properties of these newer methods are necessarily studied under certain sparsity assumptions, where (i) the number of available predictor variables (e.g., SNPs) can vastly outstrip the number of independent replicates (e.g., subjects) but (ii) the number of important variables is much smaller. Despite the many important advances in both estimation and inference in the presence of variable selection that has been made since the introduction of the lasso, numerous unresolved challenges remain and research into these problems continues.
Consequently, feature selection in genomics relies on custom combinations of filters, wrappers, embedded methods, and dimensionality-reduction. These methods have their own advantages and disadvantages that will be further discussed ( Table 2 ). The optimal process of sequencing and combining feature selection methods with domain expertise has not been well established and is more of an "art." Table 2 : Overview of feature selection categories discussed in Section 5.3
Filtering: pre-processing independent of model
In filtering, the features are pre-selected using a type of screen that is independent of the model choice. Filtering increases robustness to overfitting by reducing variance at the expense of increasing bias: 128 there is an assumption that the remaining variables are sufficient for explaining a model's behavior. There is usually also an assumption that correlation between variables can be ignored. Even prior to formal analysis, GWAS studies use quality control filters which can consist of testing for SNPs out of HardyWeinberg equilibrium, with a high missing proportion, and low minor allele frequency. 129, 130 In high dimensional problems scenarios like GWAS, millions of hypothesis tests are performed. By random chance, there is a near-guarantee of finding effects that are falsely labeled as statistically significant if there is no correction to the pre-specified significance level α. 131 Several techniques are commonly used in GWAS to correct for the probability of Type I errors, which is the risk of rejecting a true null hypothesis. 132 A Type I error can also be described as a false positive. Two important methods for controlling Type I error include the familywise error rate (probability of at least one Type I error) and the false discovery rate (the expected proportion of false discoveries). 133 One common familywise error rate method is Bonferroni correction, which involves dividing the α of a single hypothesis test (i.e., the threshold for obtaining a surprising result assuming no difference; often set at α = 0.05) by the number of independent tests performed. For example, in a GWAS with approximately 1 million independent SNPs being evaluated individually, the corrected α would be set to 0.05 ÷ 10 6 = 5×10 -8 . Use of Bonferroni correction to account for multiple hypothesis testing has become standard practice in genetic association studies, including those focused on radiotherapy outcomes. 65, 134 The main weakness of univariable filtering is that it does not account for interactions between features and thus is unable to explain non-linear behavior between features, such as epistatic interactions. 135 Epistatic interactions are difficult to find and interpret in genomics, as statistical interaction does not necessarily imply biological interacton. 120, 136, 137 In the most extreme scenario, a variable may have no marginal effect (i.e., no independent effect or main effect) and only be detected through an interaction when combined with another variable. To address this weakness in univariable filtering, multivariable methods such as the ReliefF family take an ensemble approach to rank variables. [138] [139] [140] Other options include incorporating feature selection into model building, as discussed below.
Wrapper and embedded feature selection
Wrapper methods and embedded feature selection methods both incorporate feature selection into the model building. Wrappers are model-agnostic methods that select among feature subsets by incorporating ("wrapping") the model being assessed into the feature selection process. 141 Examples include stepwise forward selection, backward elimination, and genetic algorithms. 128 Embedded methods are model-specific methods and typically multi-objective in that they balance predictive performance with model complexity. An example is regularization, which adds a penalty parameter to a method's objective function to control for complexity. While superficially similar to information theory approaches in that both control for complexity, regularization is part of the internal model optimization process whereas information criterion approaches are used for model selection. 142 Genomics uses regularization extensively to decrease the polygenic complexity and decrease variance. 143 Common usages include linear regression regularization aimed to prevent the beta coefficients from growing too large (ridge regression 144 ), to shrink the number of non-zero beta coefficients (lasso regression 125 ), or both (elastic networks 126 ). 145, 146 A related two-step method called stability selection was developed for very high dimensional variable selection. 147 A subsampling step is first used to determine the amount of regularization and is then followed by a lasso step.
Due to their ability to consider epistasis during model fitting, regularized ML methods have been combined with filters using two-stage approaches. Unlike traditional two-stage GWAS, [148] [149] [150] these combined methods add an ML step to hypothesis testing using either data split or resampling. This combination attempts to balance sensitivity with false discovery by using screening tests to detect low signal, linear interactions and ML to train cross-validated prediction models of non-linear interactions. 136 In principle, this staged design can also take advantage of plateau in the statistical power curve at high sample sizes to contribute cases to an ML method where learning error often obeys an inverse polynomial function (Figure 2 ).
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Figure 2: Sample plots of statistical power and learning curve error. Statistical power graph derived using Genomic Association Studies power calculator. 154 Learning curve assuming an inverse power law common to multiple machine learning methods. [151] [152] [153] Reproduced from Kang et al. 9 with permission by publisher Frontiers (https://www.frontiersin.org) "Screen and clean" is an example of a two-stage model that performs lasso regression ("screen") on split data using a dictionary of pairwise interaction terms followed by hypothesis testing ("clean") on the remaining data. 127 This method has been applied to model SNP interaction and main effects. 155 A similar method reverses the order of lasso and hypothesis testing.
The COMBI method for GWAS that combines a linear support vector machine (with SNPs weighted using a moving average filter) and hypothesis testing using resampling to correct for familywise error rate. 157 Using training data from a 2007 Wellcome Trust Case Control Consortium GWAS study, the authors report higher power and precision to detect SNPs replicated in independent GWAS from 2008-2015 as compared to traditional and "screen and clean" based methods. COMBI also had fewer false discoveries, with 80% of discovered SNPs being validated in prior studies.
Similar two-stage approaches have been used with random forest (RF) and chi square test to select for SNPs. 158, 159 RF and similar ensemble-tree model have been very popular due having built-in feature importance measures. 160 In simulations of GWAS, variable importance measures using RF demonstrated superior power to discover associations with disease compared to linear regression and dimensionality reduction methods. 161 While RF can provide measures of variable importance, there are limitations to inference and interpretability for variables. Generally, RFs and related approaches do not do variable selection-meaning, (a) there is no dimension reduction and (b) it is impossible to directly carry out tests of significance (without methods like resampling of synthetic data 161 ), especially when the number of predictors approaches or exceeds the number of samples. Additionally-and perhaps as a result-there is disagreement about RF's ability to detect pure epistatic interactions compared to marginal effects. 162, 163 
Unsupervised learning: feature transformation/construction
Feature transformations are popular methods for both decreasing the number of features and reconstructing the data to improve predictive performance. These methods compress the original features into fewer new ones that aim to preserve most of the information within. Unsupervised learning methods are used as they do not require labeled outputs and look for interesting structure or relationships. These relationships can be between inputs or between inputs and outputs.
Clustering methods are a general class that groups observed features into fewer features called centroids and assign every data point to one of these centroids. The most popular clustering method for feature transformation is k-means clustering. Another popular clustering methods is hierarchical clustering, which can aim to preserve the bottom-up hierarchical processes seen in biology.
Another popular transformation method is principal component analysis (PCA), which is motivated by eigenvector analysis. PCA finds the directions of highest variance in the dataset that are statistically uncorrelated (i.e., all orthogonal to each other). The direction of largest variance is the first principal component (PC), the second highest variance is the second PC, and so on. While PCA is often used for feature selection, it is also used in GWAS to control for potential confounding by ancestry or batch effects. 164, 165 Methods like k-means and PCA can be effective for basic substructures (well-separated, globular shapes) but do not work well for more irregular shapes. A class of methods called manifold learning algorithms is aimed to find low dimensional structure in high dimensional data. Multidimensional scaling (MDS) is one such method that aims to preserve information about the proximity of data points to each other. In genomics, MDS is used as an alternative to PCA. 143 A newer method called t-SNE finds a two-dimensional representation of data such that the distances between points in the 2D scatterplot match the distances between the same points in the original high dimensional dataset. [166] [167] [168] Kernel-based methods such as support vector machines can transform features in higher dimensions where analysis may be easier. 169 Neural networks are another popular ML method that specializes in constructing features within the hidden layers after being initialized with observed features.
Multi-step feature selection in radiogenomics
Oh et al. apply several feature selection methods to GWAS data for the prediction of rectal bleeding and erectile dysfunction after prostate radiotherapy. 170 The SNPs are initially pre-filtered for quality control, resulting in approximately 600,000 SNPSs in 368 patients. Stepwise forward selection of the SNPs into PCA was performed through inputting the first 1-2 principal components into logistic regression to predict binary toxicity outputs. By mapping transformed SNPs in logistic regression to predict binary toxicities, continuous "pre-conditioned outcomes" are created which are highly correlated with both the binary toxicities and the inputs. 171 The original SNPs were input into random forest regression to predict the preconditioned outcomes and validated on holdouts of the original samples. SNP importance rank was assessed using out-of-bag performance and inclusion in known biological pathways. Using this method, several genes implicated in ion transport and vascular regulation were found to be important for rectal bleeding and erectile dysfunction, respectively. This process was also applied to predict genitourinary toxicity and find associated gene ontology terms. 172 
Conclusion
As genomics assays to guide targeted systemic therapy becomes more established, the next logical step is to use genomics to improve the therapeutic ratio in radiation oncology. As discussed, several tumor radiosensitivity panels have been developed and continue to undergo validation, including GARD, PORTOS and the Bayesian network approach for multi-omics. The PORTOS assay for post-prostatectomy radiation is now listed in the NCCN guidelines under the GenomeDX Decipher ® platform. 25 Radiotoxicity models based on SNPs identified via GWAS are also undergoing active development. The high-dimensionality and lower signal-to-noise in GWAS has been challenging, but cooperative efforts by the Radiogenomics Consortium to pool cohorts and apply new methodologies aim to address these issues. 
